Eugene Williams - 20 May 2026 Form 4 Insider Report for ProMIS Neurosciences Inc. (PMN)

Reporting relationship: Director
Issuer ticker: PMN
Reported as of: 20 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 May 2026, 16:35:15 UTC
Prior SEC filing: 06 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Max A. Milbury, Attorney in Fact for Eugene Williams

Key filing fact

Eugene Williams filed Form 4 for ProMIS Neurosciences Inc. (PMN) on 22 May 2026.

Key facts

This page summarizes Eugene Williams's Form 4 filing for ProMIS Neurosciences Inc. (PMN).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 22 May 2026, 16:35.

Change

Previous filing in this sequence was filed on 06 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001927626 Primary reporting owner

Williams Eugene

Relationship: Director
Address: C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO, ONTARIO, CANADA
Signature: /s/ Max A. Milbury, Attorney in Fact for Eugene Williams
Signature date: 22 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PMN transaction Derivative

Option (right to buy)

Award

Transaction value
Shares: +5,500
Change %
Price: $0.000000^*
Shares after: 5,500
Date: 20 May 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 5,500
Exercise price: $10.77
Footnotes: F1

PMN transaction Derivative

Option (right to buy)

Award

Transaction value
Shares: +11,000
Change %
Price: $0.000000^*
Shares after: 11,000
Date: 20 May 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 11,000
Exercise price: $10.77
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.

Footnote F2

25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.